文献速递产科

普萘洛尔用于初产妇引产的双盲随机安慰剂对照试验

Propranolol for Induction of Labor in Nulliparas trial a double-blind, randomized, placebo-controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-01-06

该双盲随机安慰剂对照试验纳入240例足月单胎初产妇,随机接受单次静脉普萘洛尔2mg或安慰剂。结果显示普萘洛尔未缩短引产至阴道分娩时间或降低剖宫产率,但显著降低复合母体发病率,新生儿结局无差异。

要点

  • 单次静脉普萘洛尔2mg未缩短引产至阴道分娩时间或降低剖宫产率。
  • 普萘洛尔组复合母体发病率显著降低(28.9% vs 41.2%,RR 0.70)。
  • 产后出血和输血率在普萘洛尔组更低,新生儿结局无显著差异。

核心结论

  • 单次给予普萘洛尔引产不能缩短初产妇分娩时间或降低剖宫产率。
  • 普萘洛尔显著降低复合母体发病率,且不增加新生儿不良结局。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,纳入足月单胎初产妇240例, randomized to 2 mg静脉普萘洛尔(121例)或生理盐水安慰剂(119例)。
  • 主要结局为引产至阴道分娩时间,采用意向性分析,P≤.05为显著。

主要发现

  • 引产至阴道分娩时间普萘洛尔组13.8±5.4小时 vs 安慰剂组14.3±5.3小时(P=.58)。
  • 剖宫产率38% vs 33.6%(P=.48),活跃产程时间11.0±5.0 vs 11.2±4.5小时(P=.77),宫口开全时间12.4±5.1 vs 12.8±5.2小时(P=.60)。
  • 复合母体发病率28.9% vs 41.2%(RR 0.70,95%CI 0.49-1.00,P=.047)。
  • 产后出血率12.4% vs 21.8%(P=.05),输血率0% vs 4.2%(P=.03)。
  • 新生儿复合发病率RR 0.74(95%CI 0.44-1.22),无显著差异。

关键数值与推荐

  • 普萘洛尔组复合母体发病率28.9%,安慰剂组41.2%,RR 0.70(95%CI 0.49-1.00,P=.047)。
  • 产后出血率普萘洛尔组12.4% vs 安慰剂组21.8%(P=.05)。
  • 输血率普萘洛尔组0% vs 安慰剂组4.2%(P=.03)。

临床怎么用

  • 单次静脉普萘洛尔2mg不应用于以缩短引产时间或降低剖宫产率为目的。
  • 需权衡普萘洛尔降低母体发病率与产后出血风险的潜在获益。

局限性

  • 样本量240例,可能不足以检测次要结局的微小差异。
  • 单中心研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Propranolol hydrochloride is a nonselective beta-adrenergic antagonist that has a known activity in the myometrium. Small trials have shown that propranolol decreases the duration of induced labor, although those studies are limited by methodological variability. OBJECTIVE: Our objective was to determine whether the addition of a single dose of propranolol to induce labor in nulliparous women would decrease total time to vaginal delivery. STUDY DESIGN: This study was a double-blind, randomized, placebo-controlled trial of nulliparous patients undergoing term induction of labor with a singleton, nonanomalous gestation. Subjects were randomized to 2 mg of intravenous propranolol hydrochloride or an identical-appearing saline placebo, administered 30 minutes after starting the induction of labor. Investigators, labor floor staff, and patients were blinded to the study drug allocation. The primary outcome was time to vaginal delivery. Secondary outcomes included mode of delivery, duration of the phases of labor, time to full dilation, composite maternal morbidity, and composite neonatal morbidity. Data were analyzed by intention-to-treat analysis with a P value of ≤.05 considered significant. RESULTS: In this study, 240 patients were enrolled from December 2017 to December 2018, with 121 patients randomized to the propranolol group and 119 to the placebo group. The 2 groups had similar baseline characteristics. Of the patients randomized, 154 (64.2%) delivered vaginally. There was no significant difference in time from the start of the induction of labor to vaginal delivery (13.8±5.4 hours for propranolol vs 14.3±5.3 hours for placebo; P=.58). There was also no difference in the rate of cesarean delivery (38% vs 33.6%; P=.48), time to active labor (11.0±5.0 vs 11.2±4.5 hours; P=.77), or time to full dilation (12.4±5.1 vs 12.8±5.2 hours; P=.60) in patients receiving propranolol compared with those receiving placebo. Subjects randomized to the propranolol group had a significantly lower rate of composite maternal morbidity (28.9% vs 41.2%; risk ratio, 0.70; 95% confidence interval, 0.49-1.00; P=.047). Rates of postpartum hemorrhage (12.4% vs 21.8%; P=.05) and transfusion (0% vs 4.2%; P=.03) were also lower in the treated group. There was no significant difference in neonatal outcomes or composite morbidity (risk ratio, 0.74; 95% confidence interval, 0.44-1.22). CONCLUSION: In this study, there is no evidence that the addition of a 1-time dose of propranolol to induce labor in nulliparous women decreases time to delivery or the rate of cesarean delivery. However, propranolol significantly reduced composite maternal morbidity without adverse neonatal effects.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Bigelow CA, Pan S, Overbey JR, et al. Propranolol for Induction of Labor in Nulliparas trial a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol MFM. 2021. PMID: 33421647. doi:10.1016/j.ajogmf.2020.100301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。